Shares of Bristol Myers Squibb BMY gained 5.62% after the company announced the continuation of the phase III ADEPT-2 study on Cobenfy in psychosis associated with Alzheimer's disease. The news ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results